Novel class of targeted cancer therapies could treat myeloid leukaemias
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
List view / Grid view
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Researchers have found they can make leukaemia cells vulnerable by dislodging leukaemia stem cells from a tumour-promoting niche.
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.
A drug-like compound that can inhibit a key family of enzymes associated with several types of cancer has been developed and tested successfully in cells.
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
By deleting the CISH gene from natural killer cells made from iPSCs, researchers say they have effectively treated leukaemia in vivo and in vitro.
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Scientists in Hong Kong have developed a novel optical technique that facilitates accurate tracking of hemogenic endothelium cells in zebrafish embryos, providing new insights into the mechanisms of blood formation and potential new understanding of diseases such as leukaemia.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
Researchers investigating childhood leukaemia have discovered that increasing MLL gene expression in iPSCs drives hematopoietic stem cell production, so could be the target of new therapies.
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.